Treatment of patients with genotype 3 chronic hepatitis C- current and future therapies

Liver International

Volumn 32, Issue SUPPL. 1, 2012, Pages 141-145

  Sarin, Shiv K ^a   Kumar, Chandan K N ^a  

^a INSTITUTE OF LIVER AND BILIARY SCIENCES   (India)

Author keywords

Antivirals; Chronic hepatitic; Cirrhosis; Direct acting; HCV; Rapid virological response; Sustained virological response

Indexed keywords

2' METHYLCYTIDINE; ABT 267; ABT 450; ACH 1095; ACH 1625; ACH 2684; ALISPORIVIR; ALPHA2A INTERFERON; ANTIVIRUS AGENT; ASUNAPREVIR; AVL 192; BMS 791325; BOCEPREVIR; CILUPREVIR; CYCLOSPORIN A [4 N METHYLISOLEUCINE]; DACLATASVIR; DANOPREVIR; GNS 227; GS 9256; GS 9451; GSK 2336805; GSK 2485852; IDX 320; MK 5172; PEGINTERFERON ALPHA2B; RIBAVIRIN; SIMEPREVIR; TELAPREVIR; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALOPICITABINE; VANIPREVIR; VX 985;

ALLELE; BODY WEIGHT; CHROMOSOME 19; COST EFFECTIVENESS ANALYSIS; DIABETES MELLITUS; DRUG TOLERANCE; FATTY LIVER; GENETIC ASSOCIATION; GENOTYPE; GROUPS BY AGE; HEPATITIS C; HUMAN; LIVER FIBROSIS; META ANALYSIS (TOPIC); OUTCOME ASSESSMENT; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RACE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETROSPECTIVE STUDY; REVIEW; SEX DIFFERENCE; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT DURATION; VIRUS LOAD; VIRUS REPLICATION; VIRUS RESISTANCE;

ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; INTERLEUKINS; OLIGOPEPTIDES; POLYETHYLENE GLYCOLS; POLYMORPHISM, GENETIC; PROLINE; RECOMBINANT PROTEINS; RIBAVIRIN; SERINE PROTEINASE INHIBITORS; TIME FACTORS; VIRAL LOAD;

EID: 84855240877     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2011.02715.x     Document Type: Review

References (27)

1. Lavanchy D. The global burden of hepatitis C. Liver Int 2009; 29(Suppl. s1): 74-81.
2. Hissar SS, Goyal A, Kumar M, et al. Hepatitis C virus genotype 3 predominates in North and Central India and is associated with significant histopathologic liver disease. J Med Virol 2006; 78: 452-8.
3. Shepard CW, Finelli L, Alter MJ. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis 2005; 5: 558-67.
4. Ghany MG, Nelson DR, Strader DB, Thomas DL, Seeff LB. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology 2011; 54: 1433-44.
5. Andriulli A, Mangia A, Iacobellis A, et al. Meta-analysis: the outcome of anti-viral therapy in HCV genotype 2 and genotype 3 infected patients with chronic hepatitis. Aliment Pharmacol Ther 2008; 28: 397-404.
6. Bochud PY, Cai T, Overbeck K, et al. Genotype 3 is associated with accelerated fibrosis progression in chronic hepatitis C. J Hepatol 2009; 51: 655-66.
7. Sood A, Midha V, Hissar S, et al. Comparison of low-dose pegylated interferon versus standard high-dose pegylated interferon in combination with ribavirin in patients with chronic hepatitis C with genotype 3: an Indian experience. J Gastroenterol Hepatol 2008; 23: 203-7. Epub 2007 Jul 20.
8. Probst A, Dang T, Bochud M, et al. Role of Hepatitis C virus genotype 3 in liver fibrosis progression - a systematic review and meta-analysis. J Viral Hepat 2011; 18: 745-59.
9. Nkontchou G, Ziol M, Aout M, et al. HCV genotype 3 is associated with a higher hepatocellular carcinoma incidence in patients with ongoing viral C cirrhosis. J Viral Hepat 2011; 18: e516-22.
10. Mirandola S, Realdon S, Iqbal J, et al. Liver microsomal triglyceride transfer protein is involved in hepatitis C liver steatosis. Gastroenterology 2006; 130: 1661-9.
11. Jackel-Cram C, Babiuk LA, Liu Q. Up-regulation of fatty acid synthase promoter by hepatitis C virus core protein: genotype-3a core has a stronger effect than genotype-1b core. J Hepatol 2007; 46: 999-1008.
12. Jackel-Cram C, Qiao L, Xiang Z, et al. Hepatitis C virus genotype-3a core protein enhances sterol regulatory element-binding protein-1 activity through the phosphoinositide 3- kinase-Akt-2 pathway. J Gen Virol 2010; 91: 1388-95.
13. Moriya K, Nakagawa K, Santa T, et al. Oxidative stress in the absence of inflammation in a mouse model for hepatitis C virus-associated hepatocarcinogenesis. Cancer Res 2001; 61: 4365-70.
14. Moriya K, Fujie H, Shintani Y, et al. The core protein of hepatitis C virus induces hepatocellular carcinoma in transgenic mice. Nat Med 1998; 4: 1065-7.
15. Ghany MG, Strader DB, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009; 49: 1335-74.
16. Di Martino V, Richou C, Cervoni J-P, et al. Response-guided peg-interferon plus ribavirin treatment duration in chronic hepatitis C: meta-analyses of randomized, controlled trials and implications for the future. Hepatology 2011; 54: 789-800.
17. Manns M, Zeuzem S, Sood A, et al. Reduced dose and duration of peginterferon alfa-2b and weight-based ribavirin in patients with genotype 2 and 3 chronic hepatitis C. J Hepatol 2011; 55: 554-63.
18. Shah SR, Patel K, Marcellin P, et al. Steatosis is an independent predictor of relapse following rapid virologic response in patients with HCV genotype 3. Clin Gastroenterol Hepatol 2011; 9: 688-93.
19. Moghaddam A, Melum E, Reinton N, et al. IL28B genetic variation and treatment response in patients with hepatitis C virus genotype 3 infection. Hepatology 2011; 53: 746-54.
20. Lindh M, Lagging M, Farkkila M, et al. Interleukin 28B gene variation at rs12979860 determines early viral kinetics during treatment in patients carrying genotypes 2 or 3 of hepatitis C virus. J Infect Dis 2011; 203: 1748-52.
21. Mangia A, Thompson A, Santoro R, et al. IL28B polymorphism determines treatment response of patients with hepatitis C genotypes 2 or 3 who do not achieve a rapid virologic response. Gastroenterology 2010; 139: 821-7.
22. Freedman ND, Curto TM, Lindsay KL, et al. Everhart for the HALT-C trial group. Coffee consumption is associated with response to peginterferon and ribavirin therapy in patients with chronic hepatitis C. Gastroenterology 2011; 140: 1961-9.
23. 2A monotherapy. Dig Dis Sci 2011; 56: 3296-304.
24. Asselah T, Marcellin P. New direct-acting antivirals' combination for the treatment of chronic hepatitis C. Liver Int 2011; 31(Suppl. 1): 68-77.
25. Mathy JE, Ma S, Compton T, Lin K. Combinations of cyclophilin Inhibitor NIM811 with hepatitis C virus NS3-4A protease or NS5B polymerase inhibitors enhance antiviral activity and suppress the emergence of resistance. Antimicrob Agents Chemother 2008; 52: 3267-75.
26. Flisiak R, Horban A, Gallay P, et al. The cyclophilin inhibitor Debio-025 shows potent anti-hepatitis C effect in patients coinfected with hepatitis C and human immunodeficiency virus. Hepatology 2008; 47: 817-26.
27. Lupberger J, Zeisel MB, Xiao F, et al. EGFR and EphA2 are host factors for hepatitis C virus entry and possible targets for antiviral therapy. Nature Med 2011; 17: 589-96.